Exposure-Response Analyses to Inform the Optimal Epcoritamab Monotherapy Dosing Regimen in Relapsed or Refractory Follicular Lymphoma.
Clin PharmacokinetAug 1, 2026 (epub)
Mahipal Sinnollareddy, Kinjal Sanghavi, Leonid Gibiansky et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase I/II clinical trial evaluated the dosing regimen of epcoritamab in patients with relapsed or refractory follicular lymphoma. The study found that higher drug exposure correlated with improved efficacy, with an objective response rate of 95.2% and a complete response rate of 76.2% at the optimal 48 mg dose. The recommended 3-step step-up dosing regimen was confirmed to be effective and manageable.
Key findings
- Objective response rate of 95.2% and complete response rate of 76.2% at 48 mg dose.
- 96.2% of responders showed initial response during weekly dosing.
- 3-step dosing regimen reduced cytokine release syndrome frequency and severity compared to the 2-step regimen.
- No significant trends between drug exposure and treatment-emergent adverse events were observed.
Why it matters
Understanding the optimal dosing regimen for epcoritamab can enhance treatment efficacy in patients with relapsed or refractory follicular lymphoma, potentially leading to better patient outcomes and management of adverse effects.